Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.32 |
| ▸ | NPC1 | O15118 | 3/20 | 0.32 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | JAK3 | P52333 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21070039 | 0.92 | MCL1 (0.40) | MCL1ALDH1A1L3MBTL1MEN1KMT2A | |
| SCHEMBL21069327 | 0.91 | MCL1 (0.42) | MCL1ALDH1A1L3MBTL1MEN1KMT2A | |
| SCHEMBL21070235 | 0.91 | MCL1 (0.42) | MCL1ALDH1A1L3MBTL1MEN1KMT2A | |
| SCHEMBL30241947 | 0.81 | MCL1 (0.41) | MCL1ALDH1A1L3MBTL1MEN1KMT2A | |
| SCHEMBL12800201 | 0.79 | ALDH1A1 (0.45) | MCL1ALDH1A1L3MBTL1MEN1KMT2A | |
| SCHEMBL25988699 | 0.77 | HRH3 (0.32) | JAK3 | |
| SCHEMBL21070899 | 0.77 | MCL1 (0.36) | MCL1ALDH1A1L3MBTL1MEN1KMT2A | |
| SCHEMBL26923737 | 0.77 | MCL1 (0.36) | MCL1ALDH1A1L3MBTL1MEN1KMT2A | |
| SCHEMBL21069289 | 0.76 | BCHE (0.41) | MCL1ALDH1A1L3MBTL1MEN1KMT2A | |
| SCHEMBL21070875 | 0.76 | BCHE (0.41) | MCL1ALDH1A1L3MBTL1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11723980-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11723980-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | MCL1 1117/4885ALDH1A1 2776/4885L3MBTL1 1394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.